[1] | Amos A.H., McCarty D.J. and Zimmet P. (1997). The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabetic Medicine; 14(55): S57-S85. |
|
[2] | King H., Aubert R.E. and Herman W.H. (1998). Global burden of diabetes; 1998-2025: Prevalence, numerical estimates and projections. Diabetes Care; 21(9):1414-1431. |
|
[3] | Wild S., Roglic G., Green A., Sicree R. and King H. (2004). Global prevalence of diabetes; Estimates for the year 2000 and projections for 2030. Diabetes Care; 27(5): 1047-1053. |
|
[4] | Shaw J.E., Sicree R.A. and Zimmet P.Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice; 87(1):4-14. |
|
[5] | Whiting D.R., Guariguata L., Weil C. and Shaw J. (2011). IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice; 94(3): 311-321. |
|
[6] | Ogurtsova K., da Rocha Fernandes J.D., Huang Y., Linnencamp U., Guariguata L., Cho N.H., Cavan D., Shaw J.E. and Makaroff L.E.(2017).IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice; 128: 40-50. |
|
[7] | Siedell J.C. (2000). Obesity, insulin resistance and diabetes- a worldwide epidemic. British Journal of Nutrition; 83(51): 55-58. |
|
[8] | Nanditha A., Ma R.C.W., Ramachandran A., Snchalatha C., Chan J.C.N., Chia K.S., Shaw J.E. and Zimmet P.Z. (2016). Diabetes in Asia and the Pacific; Implications for the global epidemic. Diabetes Care; 39(3): 472-485. |
|
[9] | Warraich H.J. and Rana J.S. (2017). Dyslipidemia in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology; 6(1): 27-32. |
|
[10] | Izkhakov E., Meiltzer E. and Rubinstein A. (2003). Pathogenesis and management of diabetic dyslipidemia. Treatments in Endocrinology; 2(4): 231-245. |
|
[11] | Shah A.S., Maahs D.M., Stafford J.M., Dolan L.M., Lang W., Imperatore G., Bell R.A., Liese A.D., Reynolds K., Pihoker C., Marcovina S., D’Agostino RB. And Dabelea D. (2017). Predictors of dyslipidemia over time in youths with Type1 diabetes: for the SEARCH for Diabetes in Youths Study. Diabetes Care; 40(4): 607-613. |
|
[12] | Anabtawi A., Moriarty P.M. and Miles J.M. (2017). Pharmacologic treatment of dyslipidemia in diabetes: A case for therapies in addition to status. Current Cardiology Reports; 19: 62. |
|
[13] | Drouin-Chartier J.P., Tremblay A.J., Lepine M.C., Lemelin Y, Lamarche B. and Couture P. (2018). Substitution of dietary ω-6 PUFAs for saturated fatty acids decreases LDL, apolipoprotein-B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial. The American Journal of Clinical Nutrition; 1(1): 26-34. |
|
[14] | Siri P., Candela N., Zhang V.L., Ko C., Eusufzai S., Ginsberg H.N. and Huang L.S. (2001). Post transcriptional stimulation of the assembly and the secretion of triglyceride, apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity and insulin resistance. Journal of Biological Chemistry; 276(49): 40064-40072. |
|
[15] | Saponaro C., Gaggini M., Carli F. and Gastaldelli A. (2015). The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients; 7(11): 9453-9474. |
|
[16] | Avall K., Ali Y., Leibiger B., Moede T., Pashan M., Dicker A., Dare E., Kohler M., Ilegems E. and Abdulreda M.H. (2015). Apolipoprotein CIII links islet insulin resistance to β cell failure in diabetes. Proceedings of the National Academy of Sciences of the United States of America; 112(20): E2611-E2619. |
|
[17] | Jocken J.W.E., Goossens G.H., Popeijus H., Essens Y., Hoebers N. and Blaak E.E.(2016). Contribution of lipase deficiency to mitochondrial dysfunction and insulin resistance in hMADS adipocytes. International Journal of Obesity; 40: 507-513. |
|
[18] | Maser R.E., Lenhard M.J., Pohlig R.T. and Balagopal P.B. (2017). Pre-heparin lipoprotein lipase mass as a potential mediator in the association between adiponectin and HDL cholesterol in type 2 diabetes. Journal of Clinical and Translational Endocrinology; 7: 7-11. |
|
[19] | Schofield J.D., Liu Y., Rao-Balakrishna P., Malik R.A. and Soran H. (2016). Diabetes dyslipidemia. Diabetes Therapy; 7(2): 203-219. |
|
[20] | Hussain N., Hashmi A.S., Wasim M, Akhtar T.,Saeed S. and Ahmad T. (2018). Synergistic potential of Zingiber officinale and Curcuma longa toamelioratediabetic dysipidemia. Pakistan Journal of Pharmaceutical Science; 31(2): 491-498. |
|
[21] | De las HerasN., Valero-Munoz M., Martin-Fernandez B., Ballesteros S., Lopez-Ferre A., Ruiz- Roso B. and Lahera V. (2017). Molecular factors involved in the hypolipidemic and insulin sensitizing effects of a ginger (Zingiber officinale Roscoe) extract in rats fed a high-fat diet. Applied Physiology, Nutrition and Metabolism; 42(2): 209-215. |
|
[22] | Kononenko N.M., Chikitkina V.V., Sorokina M.V. and Ostapets M.O. (2017). The study of hypolipidemic properties of ginger extract on the model of type 2 diabetes induced by dexamethasone. News of Pharmacy; 4(92): 56-62. |
|
[23] | Jafarnejad S., Keshavarz S.A., Mahbubi S., Saremi S., Arab A., Abbasi S. and Djafanan K. (2017). Effect of ginger (Zingiber officinale) on blood glucose and lipid concentrations in diabetic and hyperlipidemic subjects: A meta-analysis of randomized controlled trials. Journal of Functional Foods; 29: 127-134. |
|
[24] | Rahimlou M., Ahmadnia H., Hekmatdoost A., Seyed M.A. and Seyed A,K, (2017). The effects of ginger supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled study. Journal of Ilam University of Medical Sciences; 25(1): 211-219. |
|
[25] | Arablou T., Aryaeia N., Valizadeh M., Shariff F., Hosseini A. and Djalali M. (2014). The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. International Journal of Food Sciences and Nutrition; 65(4): 515-520. |
|
[26] | Al-Shrafi N. M.N, and Al-Sharafi M.R.A. (2014). Study of the effects of ginger (Zingiber officinale) extract on serum lipids in hypothyroidism male rats induced by Propylthiouracil. Kufa Journal of Veterinary Medical Sciences; 5(2): 258-266. |
|
[27] | Subbaiah G.V., Mallikarjuna K., Shanmugam B., Ravi S., Taj P. And Reddy K.S. (2017). Ginger treatment ameliorates alcohol-induced myocardial damage by suppression of hyperlipidemia and cardiac biomarkers in rats. Phamacognosy Magazine; 13(1): 69-75. |
|
[28] | Lai Y.S., Lee W.C, Lin Y.E., Ho C.T., Lu K.H., Lin S.H., Panyod S., Chu Y.L. and Sheen L.Y. (2017). Ginger essential oil ameliorates hepatic injury and lipid accumulation in high-fat diet-induced non-alcoholic fatty liver disease. Journal of Agricultural and Food Chemistry; 64(10): 2062-2071. |
|
[29] | Akhani S.P., Vishwakarma S.L. and Goyal R.K. (2004). Anti diabetic activity of Zingiber officinale in streptozotocin-induced Type 1 diabetic rats. Journal of Pharmacy and Pharmacology; 56: 101-105. |
|
[30] | Elshater A.A., Salman M.M.A. and Moussa M.M.A. (2009). Effect of Ginger extract consumption on levels of blood glucose, lipid profile and kidney functions in alloxan-induced diabetic rats. Egyptian Academic Journal of Biological Sciences; 2(1): 153-162. |
|
[31] | Martinello F., Soares S.M. and Franco J.J. (2006). Hypolipidemic and antioxidant activates from Tamarindus indica pulp fruit extract in hypercholesterolemic hamsters. Food and Chemical Toxicology; 44(6): 810-818. |
|
[32] | Al-Amin Z.M., Thomson M., Al-Qattan K.K., Peltonen-Shalaby R. and Ali M. (2006).Antidiabetic and hypolipidemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. British Journal of Nutrition; 96(4): 660-666. |
|
[33] | Kergoat M. and Portha B. (1985). In vivo hepatic and peripheral insulin sensitivity in rats with non-insulin-dependent diabetes induced by streptozocin. Assessment with the insulin-glucose clamp technique. Diabetes; 34(11): 1120-6. |
|
[34] | Ozougwu J.C. and Eyo J.E. (2011). Evaluation of the activity of Zingiber officinale aqueous extracts on alloxan-induced diabetic rats. Pharmacology on line; 1: 258-269. |
|
[35] | Ramudu S.K., Mallikarjuna K. and Kesireddy S.R. (2011). Efficacy of ethanolic extract of ginger on kidney lipid metabolic profiles in diabetic rats. International Journal of Diabetes in Developing Countries; 31(2): 97-103. |
|
[36] | Al-Hoory A.S., Amreen A.N. and Hymoor S. (2013). Antihyperlipidemic effects of ginger extracts in alloxan-induced diabetes and propylthiouracil-induced hypothyroidsm in rats. Pharmacognosy Research; 5(3): 157-161. |
|
[37] | Saied J.M., Mohammed A.B. and Al-Baddy M.A. (2010). Effect of aqueous extract of ginger on blood biochemistry parameters of broiler. International Journal of Poultry Science; 9(10): 944-947. |
|
[38] | Gao H., Guan T., Li C., Zuo G., Yamahara J., Wang J and Li Y. (2012). Treatment with ginger ameliorates fructose-induced fatty liver and hypertriglyceridemia in rats: modulation of the hepatic carbohydrate response element-binding protein mediated pathway. Evidence Based Complementary and Alternative Medicine; Volume 2012: 570948. |
|
[39] | Mahluji S., Attari V.E., Mabassori M., Payahoo L., Ostadrahimi A. and Golzari S.E.J. (2013). Effect of ginger (Zingiber officinale) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients. International Journal of Food Sciences and Nutrition; 64(6): 682-686. |
|
[40] | Ismail N.S. (2014). Protective effects of aqueous extracts of cinnamon and ginger herbs against obesity diabetic rat. World Journal of Dairy and Food Sciences; 9(2): 145-153. |
|